Abstract:Immunotherapy strategies have been emerging as powerful weapons against cancer. Early clinical trials reveal that overall response to immunotherapy is low in breast cancer patients, suggesting that effective strategies to overcome resistance to immunotherapy are urgently needed. In this study, we investigated whether epigenetic reprograming by modulating histone methylation could enhance effector T lymphocyte trafficking and improve therapeutic efficacy of immune checkpoint blockade in breast cancer with focus on triple-negative breast cancer (TNBC) subtype. In silico analysis of The Cancer Genome Atlas (TCGA) data shows that expression of histone lysine-specific demethylase 1 (LSD1) is inversely associated with the levels of cytotoxic T cell-attracting chemokines (C-C motif chemokine ligand 5 (CCL5), C-X-C motif chemokine ligand 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC specimens. Tiling chromatin immunoprecipitation study showed that re-expression of chemokines by LSD1 inhibition is associated with increased H3K4me2 levels at proximal promoter regions. Rescue experiments using concurrent treatment with small interfering RNA or inhibitor of chemokine receptors blocked LSD1 inhibitor-enhanced CD8+ T cell migration, indicating a critical role of key T cell chemokines in LSD1-mediated CD8+ lymphocyte trafficking to the tumor microenvironment. In mice bearing TNBC xenograft tumors, anti-PD-1 antibody alone failed to elicit obvious therapeutic effect. However, combining LSD1 inhibitors with PD-1 antibody significantly suppressed tumor growth and pulmonary metastasis, which was associated with reduced Ki-67 level and augmented CD8+ T cell infiltration in xenograft tumors. Overall, these results suggest that LSD1 inhibition may be an effective adjuvant treatment with immunotherapy as a novel management strategy for poorly immunogenic breast tumors.

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

[Research Progress of Histone Deacetylase Inhibitor Combined with Immune Checkpoint Inhibitor in the Treatment of Tumor].

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Small molecule HDAC inhibitors: Promising agents for breast cancer treatment

HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma

HDAC-targeting epigenetic modulators for cancer immunotherapy

Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Histone Deacetylase Inhibitors as Anticancer Drugs

Advances in targeting histone deacetylase for treatment of solid tumors

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells

Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

HDACs Alters Negatively to the Tumor Immune Microenvironment in Gynecologic Cancers.

Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.

New Development of HDAC Inhibitors As Anti-Cancer Agents

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

Cyclic Peptide Histone Deacetylase Inhibitors

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors

Progress of Hdac Inhibitor Panobinostat in the Treatment of Cancer